SEROQUEL XR Drug Patent Profile

When do Seroquel Xr patents expire, and what generic alternatives are available?

Seroquel Xr is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-three drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Seroquel Xr

A generic version of SEROQUEL XR was approved as quetiapine fumarate by ACCORD HLTHCARE on March 27^th, 2012.

Summary for SEROQUEL XR

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for SEROQUEL XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	150 mg	022047	1	2008-11-17
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	50 mg	022047	1	2008-10-17
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	400 mg	022047	1	2008-06-18
SEROQUEL XR	Extended-release Tablets	quetiapine fumarate	200 mg and 300 mg	022047	1	2008-06-12

US Patents and Regulatory Information for SEROQUEL XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-001	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-003	May 17, 2007	AB	RX	Yes	No
Cheplapharm	SEROQUEL XR	quetiapine fumarate	TABLET, EXTENDED RELEASE;ORAL	022047-005	Aug 11, 2008	AB	RX	Yes	No

International Patents for SEROQUEL XR

See the table below for patents covering SEROQUEL XR around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	90593
Australia	593336
Norway	168771

Supplementary Protection Certificates for SEROQUEL XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0240228	C980022	Netherlands		PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731
0240228	SPC/GB97/086	United Kingdom		PRODUCT NAME: QUETIAPINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: UK 12619/0112 19970731; UK 12619/0113 19970731; UK 12619/0114 19970731
0240228	9/2000	Austria		PRODUCT NAME: QUETIAPIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-23460, 1-23461 1-23463 20000113; FIRST REGISTRATION: GB 12619/0112 - 12619/0114 19970731

SEROQUEL XR Market Analysis and Financial Projection

Last updated: April 25, 2026

SEROQUEL XR (quetiapine fumarate extended-release): Investment scenario and fundamentals analysis

What is SEROQUEL XR and where does it sit in the value chain?

SEROQUEL XR is an extended-release formulation of quetiapine fumarate for the treatment of psychiatric disorders. In the U.S., it is marketed by AstraZeneca under prescription-only rules.

Core commercial role

• Product form: quetiapine XR (extended-release)
• Market position: branded atypical antipsychotic with long-established clinical use and entrenched prescriber familiarity
• Value chain exposure: (1) ongoing demand from maintenance/continuation patients, (2) competitive pressure from generics and other atypicals, (3) lifecycle actions (formulation, labeling expansion where applicable) that sustain revenue against generic erosion

What are the fundamental demand drivers?

SEROQUEL XR’s demand fundamentals are shaped by three layers: (1) clinical substitution and switching behavior, (2) competitive landscape, and (3) payor and guideline dynamics.

1) Switch and persistence dynamics Extended-release (XR) formulations typically align with adherence goals. For maintenance populations, persistence can be materially higher than for short-acting dosing if tolerability and sleep-related outcomes support continued treatment. For investors, the implication is that once stabilized, a meaningful share of patients continues on therapy for longer periods, which can dampen near-term demand volatility.

2) Competitive intensity SEROQUEL XR competes in the atypical antipsychotic class against:

• Generic quetiapine (immediate-release and other XR branded or generic equivalents where available by jurisdiction)
• Other atypicals with different dosing and side-effect profiles (prescriber preference and formulary tier placement)

Generic quetiapine is the primary structural headwind in most markets once exclusivity ends. In that context, branded XR competes through perceived tolerability, dosing convenience, and formulary placement.

3) Payor and formulary The principal economics are driven by:

• Formulary tiering (preferred vs non-preferred)
• Copay and prior authorization behavior where payer policy favors lowest net cost options
• State Medicaid and managed-care contracting that determine channel mix

What is the investment scenario framework?

This scenario analysis uses a standard three-part lens: (A) revenue trajectory, (B) margin and cash conversion, (C) risk-adjusted probability of negative shocks (pricing, utilization, and legal/patent events).

Because the question is product-specific (not company-level) and because SEROQUEL XR is a mature asset with extensive historical coverage, the investment base case typically hinges on the degree of continued pricing resilience vs generic erosion rate, and the speed and depth of formulary downgrades.

A. Revenue trajectory scenario set

Base case (steady decline with persistence tail)

• Expect continued patient persistence in maintenance cohorts
• Assume gradual share erosion driven by generic substitution and formulary changes
• XR premium compresses over time through payer contracting

Upside case (slower erosion due to formulary stickiness)

• More favorable payer mix
• Reduced switch rates from XR to immediate-release generics
• Label-driven continuation patterns remain stable

Downside case (accelerated erosion and utilization pressure)

• Faster tier migration to generics
• More restrictive prior authorization
• Rising market share loss to alternative atypicals

B. Margin and cash conversion scenario set

Branded economics after generic entry

• Marketing and distribution costs usually scale with prescription volume
• Gross margin declines as net price falls via rebates and discounts to compete in tiered formularies
• Cash conversion remains a key lever for investors because manufacturing cost is relatively stable for small-molecule antipsychotics

Key sensitivity points:

• Net price (after rebates)
• Share and prescription volume
• Legal or procurement-driven pricing swings (channel-specific)

C. Risk-adjusted negative shock register

1) Structural pricing

• Aggressive payer contracting after generic penetration
• Continued net price compression from formulary pressure

2) Utilization risk

• Tightening of managed-care controls
• Patient discontinuation if tolerability issues emerge (population-level churn)

3) Patent and exclusivity events

• Litigation outcomes, if any, can create step-changes in generic entry timing
• Risk is asymmetric: adverse outcomes typically accelerate erosion; favorable outcomes delay it

What do fundamentals imply for an investor’s thesis?

For SEROQUEL XR, the investment thesis is usually not about clinical innovation. It is about how long the product maintains pricing and persistence after generic and competitive pressure.

Fundamental thesis drivers

• Persistence rate of XR regimen in maintenance patients
• Formulary accessibility and tier position across major payer groups
• Net price resilience versus generic quetiapine
• Competitive substitution dynamics within atypicals

How does IP structure typically affect the asset’s economics?

For mature branded products, the dominant IP question is not “whether IP exists” but “what is the remaining duration that prevents or delays generic competition and interchangeable competition by formulation.”

The main investor-relevant IP mechanics usually include:

• Composition of matter coverage (often expired)
• Formulation and method-of-use claims (can extend barriers if they survive and cover commercial activity)
• Exclusivity not tied to patents in certain jurisdictions and regulatory frameworks (can delay generic approvals or provide market protection)

SEROQUEL XR’s economic profile fits a mature life-cycle: investors typically focus on generic entry timing and claim-specific litigation outcomes rather than on any ongoing robust patent runway.

What are the practical market signals investors should track?

A product-level monitoring package for SEROQUEL XR typically includes:

Demand signals

• Prescription volume trends by geography and channel
• Persistence rates in treated cohorts (where available via analytics vendors)
• New start vs continuation mix

Pricing and contracting signals

• Net price changes and rebate intensity
• Formulary tier movement (especially Medicare Advantage and commercial managed care)
• Prior authorization utilization rates

Competitive signals

• Share shift vs other atypicals with favorable formulary positioning
• Generic uptake rates by strength and dosage form

Where are the largest upside and downside levers?

Upside levers

• Sustained XR share due to adherence and tolerability-driven persistence
• Continued payer acceptance and stable net pricing
• Slower generic substitution than the historical norm in key markets

Downside levers

• Rapid payer downgrade to lower-cost alternatives
• Step-change generic entry acceleration tied to litigation/IP outcomes
• Utilization headwinds if treatment patterns shift away from quetiapine class for relevant indications

What is the investment conclusion for SEROQUEL XR?

SEROQUEL XR is a mature, branded small-molecule psychiatric asset where the investment outcome is largely determined by pricing decay speed and patient persistence against generic and class competition. The highest-ROI diligence focuses on payer contracting and formulary behavior rather than on near-term clinical differentiation.

---

Key Takeaways

• SEROQUEL XR is a branded quetiapine fumarate extended-release psychiatric product with mature market dynamics.
• The investment profile is driven by net price resilience, formulary positioning, and maintenance persistence, not by near-term innovation.
• The key asymmetric risks are accelerated generic erosion and payer-driven net price compression.
• Investors should prioritize prescription mix, tier status, prior authorization policy, and generic uptake velocity as the leading indicators of revenue trajectory.

---

FAQs

1) Is SEROQUEL XR mainly a growth or cash-cow story?

Cash-cow. The economics depend on durability of branded demand and pricing after generic pressure, with growth typically limited in mature markets.

2) What determines whether erosion is slow or fast for XR products like SEROQUEL XR?

XR persistence and payer tiering. Higher XR continuation and stable formulary access slow revenue decay.

3) Does competition come mainly from generic quetiapine or other antipsychotics?

Both, but generic quetiapine is the structural anchor for price erosion, while other atypicals affect share and formulary outcomes.

4) What metrics best predict next-quarter direction?

Net price movements (after rebates), prescription volume trends, and formulary tier changes in major payer contracts.

5) Where do step-changes in earnings typically originate?

Litigation and claim outcomes that alter generic entry timing, and payer contract renegotiations that change net pricing and access.

---

References (APA)

[1] AstraZeneca. (n.d.). Seroquel XR (quetiapine fumarate) prescribing information. AstraZeneca.
[2] U.S. Food and Drug Administration. (n.d.). Drug approvals and labeling information for Seroquel XR. FDA.